V. Vasilkova, T. Mokhort, L. Korotaeva, Y. Yarets, I. Pchelin, V. Bayrasheva, O. Shestovets, Y. Borovets, E. Naumenko, N. Filiptsova
Aim: to assess the relationship of proinflammatory cytokines and chemokines with the levels of natriuretic peptides in patients with diabetes mellitus (DM). Materials and methods. A total of 155 patients (14 men and 61 women) with type 1 and type 2 diabetes, aged 34 to 84 years, were examined. All patients underwent standard clinical and laboratory examination, with an assessment of the levels of pro-inflammatory cytokines (interleukin 6 (IL-6), tumour necrosis factor alpha (TNF-alpha), chemokines (monokine induced by interferon-gamma (MIG), regulated upon activation, normal T cell expressed and presumably secreted (RANTES), growth factors (fibroblast growth factor-23 (FGF-23), vascular endothelial growth factor (VEGF-A), natriuretic peptides (B‐type natriuretic peptide (BNP), N‐terminal fragment of B‐type natriuretic peptide (proBNP). Renal function was assessed based on the levels of serum creatinine, glomerular filtration rate (GFR), which was calculated according to the CKD-EPI formula, and albuminuria, which was assessed as albumin/creatinine ratio (A/C). An echocardiographic examination was conducted according to the standard protocol with the calculation of dimensional, volume and speed characteristics. Statistical data analysis was performed using smSTATA 14.2 for Mac (2018).
keywords: diabetes mellitus, chronic heart failure, interleukin-6

for references: V. Vasilkova, T. Mokhort, L. Korotaeva, Y. Yarets. Early and alternative markers of chronic heart failure in patients with diabetes mellitus. Neotlozhnaya kardiologiya i kardiovaskulyarnye riski (Emergency cardiology and cardiovascular risks), 2021, vol. 5, no. 1, pp. 1122–1127.

References
1. Christodoulidis G., Vittorio T.J., Fudim M., Lerakis S., Kosmas C.E. Inflammation in coronary artery disease. Cardiol Rev, 2014, vol. 22, no. 6, pp. 279-288.
2. Boudina S., Abel E.D. Diabetic cardiomyopathy revisited. Circulation, 2007, vol. 115, pp. 3213-3223.
3. Ruparelia N., Chai J.T., Fisher E.A., Choudhury R.P. Inflammatory processes in cardiovascular disease: a route to targeted therapies. Na. Rev Cardiol, 2017, vol. 14, pp. 133-144.
4. Volpato S., Guralnik J.M., Ferrucci L., Balfour J., Chaves P., Fried L.P., Harris T.B. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women’s health and aging study. Circulation, 2001, vol. 103, pp. 947-953.
5. Upadhyay R.K. Emerging risk biomarkers in cardiovascular diseases and disorders. J. Lipids, 2015. doi: 10.1155/2015/971453.
6. Sun Y. Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc Res, 2009, vol. 81, pp. 482-490.
7. Pitsavos C., Panagiotakos D.B, Menotti A., Chrysohoou C., Skoumas J., Stefanadis C., Dontas A., Toutouzas P. Forty-Year Follow-Up of Coronary Heart Disease Mortality and Its Predictors: The Corfu Cohort of the Seven Countries Study. Prev Cardiol, 2003, vol. 6, pp. 155-160.
8. Kosmas C.E., Silverio D., Tsomidou C. The Impact of Insulin Resistance and Chronic Kidney Disease on Inflammation and Cardiovascular Disease. Clin Med Insights Endocrinol Diabetes, 2018, vol.11, pp.12-16. doi: 10.1177/1179551418792257.
9. Bongartz G.L., Cramer M.J., Doevendans P.A., Joles J.A., Braam B. The severe cardiorenal syndrome: Guyton revisited. Eur Heart J, 2005, vol. 26, no. 1, pp. 11-17.
10. Feldman A.M., Brostow M.R., Parmley W.W., Carson P.E., Pepine C.J., Gilbert E.M., Strobeck J.E., Hendrix G.H., Powers E.R., Bain R.P. et al. Effects of vesnarinone on norbidity and mortality in patients with heart failure. New Engl J Med, 1993, vol. 329(3), pp. 149-155. doi: 10.1056/NEJM199307153290301.
11. Westman P.C., Lipinski M.J., Luger D., Waksman R., Bonow R.O., Wu E., Epstein S.E. Infammation as a driver of adverse left ventricular remodeling after acutemyocardial infarction. J Am Coll Cardiol, 2016, vol. 67, no. 17, pp. 2050-2060. doi: 10.1016/j.jacc.2016.01.073.
12. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2016. Eur Heart J, 2016, vol. 37, pp. 2129-2200.
13. Maisel A., Mueller C., Adams K., Anker S.D., Aspromonte N., Cleland J.G.F., Cohen-Solal A., Dahlstrom U., DeMaria A., DiSomma S., Filippatos G.S., Fonarow G.C., Jourdain P., Komajda M., Liu P.P., McDonagh T., McDonald K., Mebazaa A., Nieminen M.S., Peacock W.F., Tubaro M., Valle R., Vanderhyden M., Yancy C.W., Zannad F., Braunwald E. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail, 2008, vol. 10, no. 9, pp. 824-839. doi: 10.1016/j.ejheart.2008.07.014.
14. Madamanchi C., Alhosaini H., Sumida A., Runge M.S. Obesity and natriuretic peptides, BNP and NT-proBNP: Mechanisms and diagnostic implications for heart failure. Int J Cardiol, 2014, vol. 176 (3), pp. 611-617. doi: 10.1016/j.ijcard.2014.08.007.
15. Moiseev V.S., Muchin N.A., Kobalava Zh.D., Villeval’de S.V., Efremovzeva M.A., Kozlovskaya L.V., Kotovskaya Yu.V., Fomin V.V., Shal’nova S.A., Ageev F.T., Arutyu-nov G.P., Boyzov S.A., Borisov I.A., Volkova E.G., Galyavich A.S., Glezer M.G., Grinshteyn Yu.I., Dobronravov V.A., Drapkina O.M., Duplyakov D.V. i dr. Funkzional’noe sostoyanie pochek i prognozirovanie serdechno-sosudistogo riska (Renal function and prediction of cardiovascular risk). Kardiovaskulyarnaya terapiya i profilaktika, 2008, vol. 7, no. 6(3), s. 1-20. (in Russian).
16. Plischke M., Neuhold S., Kohl M., Heinze G., Sunder-Plassmann G., Pacher R., Hülsmann M. Renal function in heart failure: a disparity between estimating function and predicting mortality risk. Eur J Heart Fail, 2013, vol. 15, no. 7, pp. 763-770.
17. Ronco C., Chionh C.Y., Haapio M., Anavekar N.S., House A., Bellomo R. The cardiorenal syndrome. Blood Purif, 2009, vol. 27, no. 1, pp. 114126. doi: 10.1159/000167018.
18. Hedayat M., Mahmoudi M.J., Rose N.R., Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev, 2010, vol. 15, no. 6, pp. 543-562. doi: 10.1007/s10741-010-9168-4.
19. de Groote P., Ennezat P.V., Mouquet F. Bisoprolol in the treatment of chronic heart failure. Vasc Health Risk Manag, 2007, vol. 3, no. 4, pp.431-439.
20. Boffa G.M., Zaninotto M., Sartor R., Mion M., Berton A., Pasqualetto C., Razzolini R., Plebani M. Interleukin-6 and tumor necrosis factor-alpha as biochemical markers of heart failure:a head-to-head clinical comparison with B-type natriuretic peptide. J Cardiovasc Med(Hagerstown), 2009, vol. 10, no 10, pp. 758-764. doi: 10.2459/JCM.0b013e32832ce8e2.
21. Salvador A.M., Nevers T., Velázquez F., Aronovitz M., Wang B., Abadía Molina A., Jaffe I.Z., Karas R.H., Blanton R.M., Alcaide P. Intercellular adhesion molecule regulates left ventricular leukocyte infiltration, cardiac remodeling, and functionin pressure overload-induced heart failure. J Am Heart Assoc, 2016, vol. 5, p. e003126.
22. Glezeva N., Baugh J.A., Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Fail Rev, 2014, vol.19, pp. 681-694.
File extension: pdf (1.24 MB)